A prospective cross-sectional study published in Gynecologic Oncology reports that lower fasting serum GLP-1 levels were independently associated with endometrial cancer in obese, non-diabetic women. The researchers measured the hormone in 180 women undergoing endometrial biopsy for abnormal uterine bleeding.

GLP-1 is the gut hormone that the weight-loss drug class is built to mimic, semaglutide and tirzepatide among them. Here it is not being given as a drug at all: the researchers were measuring what the body produces on its own, by ELISA assay, and asking whether that number tracks with what the biopsy eventually showed.

Three groups, one gradient

The 180 women were split evenly into three groups of 60: endometrial polyp, endometrial hyperplasia, and endometrioid-type endometrial cancer. Mean GLP-1 fell step by step across those categories, 14.6 plus or minus 3.1 pg/mL in the polyp group, 11.2 plus or minus 2.8 in hyperplasia, and 7.4 plus or minus 2.1 in cancer, with p less than 0.001.

Key results

In multivariable analysis adjusted for BMI, HbA1c, hypertension, CRP and CA-125, lower GLP-1 stayed independently associated with cancer at an adjusted odds ratio of 0.744 per 1 pg/mL increase, 95% CI 0.636 to 0.871. Increasing age also held, at an adjusted OR of 1.320.

The discrimination figure is the one that will get attention: an AUC of 0.94, 95% CI 0.90 to 0.97, with an optimal cutoff of 9.12 pg/mL giving 86.0% sensitivity and 91.6% specificity. That is a strong curve for a single blood analyte, and it is the reason the authors raise the word biomarker at all.

The inflammation question

GLP-1 was negatively correlated with CRP, at rho of -0.293, which invites the obvious objection that this is just systemic inflammation wearing a hormone's name. The authors adjusted for CRP anyway and the association survived, which they say suggests the relationship may not be explained by inflammation alone.

Limitations

This is a single cross-sectional sample of 180 women, all obese and all non-diabetic, all presenting with abnormal uterine bleeding. A cross-sectional design cannot establish which came first, and the authors state that prospective multicenter validation is required before the cutoff means anything outside this cohort.

Bottom line

The authors position serum GLP-1 as a possible adjunctive tool for risk stratification, not a test. Whether a 9.12 pg/mL threshold replicates anywhere else is the unsettled question.